SELP and breast carcinoma: Jafari et al. developed fucoidan–doxorubicin nanoparticles to target P-selectin, enhancing the delivery and cytotoxicity of doxorubicin specifically to cancer cells with high P-selectin expression, such as the MDA-MB-231 breast cancer cell line, thus minimizing the side effects associated with doxorubicin [23].